Estimated half-life of SARS-CoV-2 anti-spike antibodies more than double the half-life of anti-nucleocapsid antibodies in healthcare workers

Documenti analoghi

• Detection of Nucleocapsid Antibody to SARS-CoV-2 is More Sensitive than Antibody to Spike Protein in COVID-19 Patients
  di: Burbelo, Peter D., et al.
  Pubblicazione: (2020)
• Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals
  di: Brochot, Etienne, et al.
  Pubblicazione: (2020)
• Alphavirus spike-nucleocapsid interaction and network antibodies.
  di: Suomalainen, M, et al.
  Pubblicazione: (1992)
• Immunoassays for anti-SARS-CoV-2 antibodies: recent insights
  di: Van Elslande, Jan, et al.
  Pubblicazione: (2021)
• Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection
  di: Van Elslande, Jan, et al.
  Pubblicazione: (2021)